Clinical Trial Update: Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) [Phase 2]

View source ↗

Summary

Phase 2 study ZZ-First evaluating the combination of enzalutamide and talazoparib in metastatic hormone-sensitive prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Talzenna (talazoparib)
• Xtandi (enzalutamide)

Snippet

Sponsor: MedSIR | Conditions: Metastatic Prostate Cancer | Phase 2 | Status: COMPLETED